Effects of multiwavelength photobiomodulation for the treatment of traumatic soft tissue injuries associated with bone fractures: A double‐blind, randomized controlled clinical trial — Frederico Carlos Jaña Neto (2023) | RDL Network
Effects of multiwavelength photobiomodulation for the treatment of traumatic soft tissue injuries associated with bone fractures: A double‐blind, randomized controlled clinical trial
Article 2023 en
Authors
FN
Frederico Carlos Jaña Neto
AM
Ana Luiza Cabrera Martimbianco
RM
Raquel Agnelli Mesquita‐Ferrari
Abstract
1 min read
This study evaluated the efficacy and safety of multiwavelength photobiomodulation (MPBM) in healing soft tissue injuries associated with tibial and/or ankle fractures. Participants were randomized into the MPBM or control group. Primary outcome was wound healing, measured by the Bates-Jensen scale. Assessments were performed daily. Twenty-seven hospitalized adults were included. MPBM showed an improvement in the daily mean Bates-Jensen scale (MPBM 32.1 vs. control 34.2; p = 0.029), daily mean pain score change (MPBM 0.5 vs. control 0.2; p = 0.04) and occurrence of infection at the site of the external fixator pins (MPBM 15.3% vs. control 57.1%; p = 0.02). MPBM group also showed faster-wound resolution (MPBM 13.1 vs. control 23.1 days). Subgroup analysis showed improvement in the MPBM group among less severe patients on the Bates-Jensen scale (MPBM 27.4 vs. control 34.7; p = 0.0081) and mean time for wound resolution (MPBM 7.0 vs. control 14.6 days; p = 0.03). MPBM appears safe and effective in reducing wound resolution time, infection in the surgical pin sites, reported pain and time before definitive surgery.
Lew Lim, Nazanin Hosseinkhah, Mark Van Buskirk, Andrea Berk, Genane Loheswaran, Zara Abbaspour, Mahta Karimpoor, Alison Smith, Kai Fai Ho, Abhiram Pushparaj, Michael Zahavi, Alexander White, Jonathan Rubine, Brian Zidel, Christopher Henderson, Russell Gene Clayton, David Roy Tingley, David Miller, Mahroo Karimpoor, Michael R Hamblin
Discussion(0)
No comments yet. Be the first to comment.